Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Ontario Votes 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
3.700
+0.050 (+1.37%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
28
29
Next >
The "Rags-To-Riches" Portfolio: An Update
March 18, 2023
Cannabis, psychedelic, and plant-based food stocks performed extremely poorly in 2022, down 73% vs. 2021 but perhaps some of them will bounce back with major returns in 2023.
Via
Talk Markets
Psychedelic Stock Gainers And Losers From March 17, 2023
March 17, 2023
Via
Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
March 16, 2023
Via
Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
March 15, 2023
Via
Benzinga
COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression
March 14, 2023
COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TR
Via
Benzinga
Where Compass Pathways Stands With Analysts
March 10, 2023
Via
Benzinga
Earnings Preview: Compass Pathways
February 27, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
March 14, 2023
Via
Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
March 13, 2023
Via
Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
March 10, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From March 9, 2023
March 09, 2023
Via
Benzinga
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
March 08, 2023
Via
Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
March 07, 2023
Via
Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...
Via
Benzinga
Compass Pathways - Entering A Brave New World
March 07, 2023
A look at what Compass Pathways is focused on, its clinical trial progress to date, its latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From March 6, 2023
March 06, 2023
Via
Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
March 06, 2023
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Via
Benzinga
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market
March 06, 2023
Investing now is an admittedly risky bet, but the payoff could be massive.
Via
The Motley Fool
2 Growth Stocks With Incredible Potential in the Next 5 Years
March 06, 2023
Neither is profitable, but both could be on the verge of massive booms in revenue.
Via
The Motley Fool
Cybin, GH Research Among Top Psychedelic Movers Of Today
March 03, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From March 2, 2023
March 02, 2023
Via
Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
March 01, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2023
February 28, 2023
Via
Benzinga
COMPASS Pathways Shares Q4 & Year-End 2022 Financials, Advances Phase 3 Psilocybin Trials
February 28, 2023
Mental healthcare biotech COMPASS Pathways (NASDAQ: CMPS) reported its financial results for the fourth quarter and year-end 2022 and provided an update on recent pipeline and business progress....
Via
Benzinga
Compass Pathways Plc (CMPS) Q4 2022 Earnings Call Transcript
February 28, 2023
CMPS earnings call for the period ending December 31, 2022.
Via
The Motley Fool
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
February 28, 2023
From
COMPASS Pathways
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From February 27, 2023
February 27, 2023
Via
Benzinga
Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD
February 26, 2023
The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From February 24, 2023
February 24, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From February 23, 2023
February 23, 2023
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
28
29
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.